Janney Montgomery Scott started coverage on shares of PLx Pharma (NASDAQ:PLXP) in a research note issued to investors on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $14.00 price objective on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of PLx Pharma from a sell rating to a hold rating in a research report on Thursday, October 12th. ValuEngine raised shares of PLx Pharma from a strong sell rating to a sell rating in a research report on Monday, December 4th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $11.08.

PLx Pharma (NASDAQ PLXP) opened at $6.90 on Friday. The company has a current ratio of 8.99, a quick ratio of 8.88 and a debt-to-equity ratio of 0.56. The company has a market cap of $60.18, a PE ratio of -1.37 and a beta of 1.82. PLx Pharma has a 12-month low of $5.60 and a 12-month high of $12.80.

PLx Pharma (NASDAQ:PLXP) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). equities research analysts expect that PLx Pharma will post -1.71 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in PLx Pharma stock. Susquehanna International Group LLP bought a new stake in shares of PLx Pharma Inc (NASDAQ:PLXP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 229,800 shares of the biotechnology company’s stock, valued at approximately $1,413,000. Susquehanna International Group LLP owned 5.24% of PLx Pharma as of its most recent filing with the Securities and Exchange Commission. 21.87% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “PLx Pharma (PLXP) Research Coverage Started at Janney Montgomery Scott” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/01/23/plx-pharma-plxp-research-coverage-started-at-janney-montgomery-scott-3.html.

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.